First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples